Idorsia Ltd

Latest Results (09.11.2025):

Idorsia Ltd's 9-month 2025 financial results reveal strong momentum, highlighted by a dramatic >130% year-on-year increase in QUVIVIQ sales and significant improvements in cost management. The company has recorded robust revenue growth and efficient expense control, positioning itself closer to achieving profitability by the end of 2027.

Strong QUVIVIQ Sales Growth

For the nine months of 2025, Idorsia Ltd reported global net sales (excluding partner sales) of CHF 91 million for QUVIVIQ, reflecting a >130% increase from 9M 2024. The company reaffirmed its full-year guidance of around CHF 130 million in QUVIVIQ net sales, underlining its growing market traction.

Improved Operational Efficiency

Excluding one-off gains, operating expenses decreased by CHF 84 million compared to 9M 2024, driven by a reduction in both R&D and SG&A expenses. This disciplined cost management has contributed to a narrower net loss, supporting the ongoing financial turnaround.

Enhanced Financial Performance

In 9M 2025, Idorsia Ltd's net revenue surged to CHF 173 million from CHF 53 million in the same period of the previous year, with the US GAAP net loss improving to CHF 34 million (or CHF 0.17 per share) compared to a net loss of CHF 79 million (or CHF 1.00 per share) in 9M 2024, reflecting the impact of both revenue growth and cost efficiencies.

Strong Liquidity and Financing Position

Idorsia Ltd secured CHF 65.6 million in financing, extending its cash runway into 2028 and reinforcing its financial position. These strategic financing activities, together with robust sales performance, bolster confidence in achieving overall profitability in the near term.